Oncolytics Biotech's (ONCY) Sell (E+) Rating Reiterated at Weiss Ratings

Key Points

• Oncolytics Biotech's stock has received a "sell (e+)" rating from Weiss Ratings, which has been reiterated in a recent report.
• Despite the negative rating from Weiss, a number of analysts have issued mixed ratings, with four analysts recommending a "Buy" rating and one upgrading it to "Hold."
• The company's stock opened at $1.28 and has a market capitalization of $128.46 million, with an average target price of $5.00 according to MarketBeat.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report)'s stock had its "sell (e+)" rating reiterated by investment analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

A number of other equities analysts have also recently issued reports on the stock. Wall Street Zen upgraded shares of Oncolytics Biotech from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Lake Street Capital started coverage on shares of Oncolytics Biotech in a research report on Wednesday, August 13th. They set a "buy" rating and a $7.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $5.00.

Oncolytics Biotech Stock Performance

ONCY stock opened at $1.28 on Wednesday. The company has a market capitalization of $128.46 million, a PE ratio of -4.74 and a beta of 1.24. Oncolytics Biotech has a one year low of $0.33 and a one year high of $1.51. The company's 50 day moving average price is $1.15 and its two-hundred day moving average price is $0.83.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.06. On average, research analysts predict that Oncolytics Biotech will post -0.28 EPS for the current year.

Institutional Trading of Oncolytics Biotech

A hedge fund recently raised its stake in Oncolytics Biotech stock. Seeds Investor LLC raised its holdings in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) by 17.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 223,767 shares of the company's stock after purchasing an additional 33,826 shares during the quarter. Seeds Investor LLC owned 0.23% of Oncolytics Biotech worth $173,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.82% of the company's stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.